Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 9/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.64 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.64 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.64 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.64 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.64 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.64 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3106327 | 0.99 | HSD11B1 (0.67) | HSD11B1ALDH1A1MAPK1OPRM1OPRK1 | |
| SCHEMBL1837629 | 0.95 | CHRM1 (0.65) | HSD11B1ALDH1A1MAPK1OPRM1OPRK1 | |
| SCHEMBL22716722 | 0.92 | HSD11B1 (0.62) | HSD11B1ALDH1A1MAPK1OPRM1OPRK1 | |
| SCHEMBL4402050 | 0.90 | CHRM1 (0.66) | HSD11B1ALDH1A1MAPK1OPRM1OPRK1 | |
| SCHEMBL2996511 | 0.90 | CHRM1 (0.66) | HSD11B1ALDH1A1MAPK1OPRM1OPRK1 | |
| SCHEMBL2993157 | 0.90 | CHRM1 (0.66) | HSD11B1ALDH1A1MAPK1OPRM1OPRK1 | |
| SCHEMBL29872667 | 0.88 | HSD11B1 (0.67) | HSD11B1ALDH1A1MAPK1OPRM1OPRK1 | |
| SCHEMBL5774178 | 0.88 | HSD11B1 (0.67) | HSD11B1ALDH1A1MAPK1OPRM1CHRM1 | |
| SCHEMBL1760919 | 0.88 | HSD11B1 (0.67) | HSD11B1ALDH1A1MAPK1OPRM1OPRK1 | |
| SCHEMBL22716742 | 0.86 | HSD11B1 (0.54) | HSD11B1ALDH1A1MAPK1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023064195-A1 | CGRP ANTAGONISTS FOR TREATING TRIGEMINAL NEURALGIA | PFIZER IRELAND PHARMACEUTICALS (IE) | 2023-04-20 | — | — | WO | claimed |
| WO-2023034467-A2 | CGRP ANTAGONISTS FOR TREATING SKIN CONDITIONS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2023-03-09 | — | — | WO | claimed |
| WO-2023034466-A1 | CGRP ANTAGONISTS FOR TREATING PSORIASIS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2023-03-09 | — | — | WO | claimed |
| EP-1539766-B1 | CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2016-12-21 | — | — | EP | claimed |
| EP-2160098-B9 | USE OF COMPOUNDS HAVING A MONOGALACTOSYLDIACYLGLYCEROL SYNTHASE INHIBITORY ACTIVITY AS HERBICIDE OR ALGAECIDE, HERBICIDE AND ALGAECIDE COMPOSITIONS | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2011-05-18 | — | — | EP | claimed |
| US-7842808-B2 | calcitonin gene-related peptide receptors antagonists such as 4-(2-Oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidine-1-carboxylic acid[2-(1,4-dioxa-8-aza-spiro [4.5]dec-8-yl)-1-(1H-indol-5-ylmethyl)-2-oxo-ethyl]-amide, used for treating headaches, pain, hot flashes or respiratory system disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-11-30 | — | — | US | claimed |
| EP-2160098-B1 | USE OF COMPOUNDS HAVING A MONOGALACTOSYLDIACYLGLYCEROL SYNTHASE INHIBITORY ACTIVITY AS HERBICIDE OR ALGAECIDE, HERBICIDE AND ALGAECIDE COMPOSITIONS | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2010-11-10 | — | — | EP | claimed |
| EP-2027132-B1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-09-15 | — | — | EP | claimed |
| EP-2160098-A2 | USE OF COMPOUNDS HAVING A MONOGALACTOSYLDIACYLGLYCEROL SYNTHASE INHIBITORY ACTIVITY AS HERBICIDE OR ALGAECIDE, HERBICIDE AND ALGAECIDE COMPOSITIONS | Commissariat a L'Energie Atomique (FR) | 2010-03-10 | — | — | EP | claimed |
| EP-2155676-A2 | COMPOUNDS WITH ANTIPARASITIC ACTIVITY, APPLICATIONS THEREOF TO THE TREATMENT OF INFECTIOUS DISEASES CAUSED BY APICOMPLEXANS | Commissariat à l'Energie Atomique (FR) | 2010-02-24 | — | — | EP | claimed |
| WO-2007134958-A1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-29 | — | — | WO | claimed |
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | BRINKMAN JOHN A | 2007-11-22 | — | — | US | claimed |
| US-20070232600-A1 | ANTI-MIGRAINE TREATMENTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-04 | — | — | US | claimed |
| US-20070149503-A1 | ANTI-MIGRAINE SPIROCYCLES | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | claimed |
| US-7220862-B2 | Calcitonin gene related peptide receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-22 | — | — | US | claimed |
| EP-1539766-A1 | CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2005-06-15 | — | — | EP | claimed |
| CN-1602191-A | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK AS (DK) | 2005-03-30 | — | — | CN | claimed |
| US-20040204397-A1 | Calcitonin gene related peptide receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | claimed |
| US-20040063735-A1 | Calcitonin gene related peptide receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | claimed |
| WO-2003104236-A1 | CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063735-A1 | Calcitonin gene related peptide receptor antagonists | CALCRL, CALCA, CALCR | HSD11B1 1033/4885ALDH1A1 2525/4885MAPK1 656/4885 |
| US-20070149503-A1 | ANTI-MIGRAINE SPIROCYCLES | CALCRL, CALCR, CALCA | HSD11B1 621/4885ALDH1A1 1998/4885MAPK1 1317/4885 |
| US-20070232600-A1 | ANTI-MIGRAINE TREATMENTS | BDKRB2, PTGIR, CALCRL | HSD11B1 966/4885ALDH1A1 2510/4885MAPK1 1080/4885 |
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | ADORA2B, UTS2R, TBXA2R | HSD11B1 2787/4885ALDH1A1 676/4885MAPK1 1615/4885 |
| US-20040204397-A1 | Calcitonin gene related peptide receptor antagonists | CALCRL, CALCA, CALCR | HSD11B1 1033/4885ALDH1A1 2525/4885MAPK1 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.